SCHEDULE: BlackRock Reports OptimizeRx Stake
Schedule 13G Filing
BlackRock, Inc. has updated its Schedule 13G filing to reflect beneficial ownership of OptimizeRx Corp. common stock.
Summary
- BlackRock, Inc. has filed an amendment to its Schedule 13G, reporting its beneficial ownership of OptimizeRx Corp. common stock.
- As of June 30, 2026, BlackRock, Inc. beneficially owns 342,250 shares of OptimizeRx Corp. common stock.
- This ownership represents 1.8% of the class of securities.
- BlackRock, Inc. has sole voting power and sole dispositive power over these shares.
- The filing indicates that various persons have the right to receive or direct dividends or sale proceeds, but no single person holds more than five percent of the total outstanding shares.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this filing as neutral, as it is a routine disclosure of beneficial ownership by an institutional investor and does not provide new operational or financial information about the company.
Positives
- BlackRock, Inc. maintains a significant, though not controlling, stake in OptimizeRx Corp.
- The filing confirms BlackRock's ongoing investment in the company.
Negatives
- The filing does not contain any negative financial or operational information about OptimizeRx Corp. itself, as it is a disclosure of beneficial ownership by a third party.
Risks
- The filing does not explicitly mention any risks related to OptimizeRx Corp. or BlackRock's investment.
Future Outlook
The filing does not contain forward-looking statements or guidance from OptimizeRx Corp. It is a disclosure of beneficial ownership by BlackRock, Inc.
Industry Context
StockSavvy.ai notes that Schedule 13G filings by large institutional investors like BlackRock are common and indicate significant holdings. This filing confirms BlackRock's position as a notable shareholder in the health technology sector where OptimizeRx operates.
Stakeholder Impact
- Shareholders: The filing confirms BlackRock's substantial investment, which can be seen as a positive signal of confidence in the company's prospects.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Previous power of attorney dated for BlackRock, Inc. |
| 2025-01-21 | Date power of attorney was executed by BlackRock, Inc. |
| 2026-06-30 | Date of event requiring filing of Schedule 13G amendment. |
| 2026-07-29 | Date of signature for the Schedule 13G filing. |
Keywords
OptimizeRx Corp, BlackRock, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Securities
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.